ArticleJournal for immunotherapy of cancer2026

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.

Ecaterina E Dumbrava et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.